Polaryx Therapeutics (PLYX) Proxy filing summary

Executive summary

• Annual meeting scheduled for September 10, 2026, to be held virtually, with voting on director elections and auditor ratification.

• Proxy materials and annual report for 2025 are available online, with voting accessible via internet, mail, or during the meeting.

• Record date for voting is July 27, 2026, with 49,845,993 shares outstanding.

Voting matters and shareholder proposals

• Shareholders will vote to elect two Class I directors for terms ending in 2029.

• Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Board recommends voting FOR both proposals.

• Shareholder proposals for the 2027 meeting must be submitted between May 13, 2027 and June 12, 2027, or by March 30, 2027 for inclusion under Rule 14a-8.

Board of directors and corporate governance

• Board is classified into three classes with staggered three-year terms; only Class I directors are up for election in 2026.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with independent directors.

• Board leadership structure includes a combined CEO/Chair and a lead independent director.

• Code of Business Conduct and Ethics and Insider Trading Policy are in place.

• All directors attended at least 75% of meetings in 2025.